DnaAcos is a privately-owned biopharmaceutical company; the Norwegian Radium Hospital Research Foundation being the largest investor.  The comp...
Read more...

SF53 Assay – A positive screen for novel antibiotics DNA replication is crucial for bacteria cells to survive and represents a novel target for deve...
Read more...

Management team Harald Dugstad holds a M. Sc. in chemistry from Oslo University. He has held management positions and worked with IP strategy i...
Read more...

The Company Strategy: DnaAcos will screen libraries and take candidate drugs from the discovery phase through early pre-clinical development in coll...
Read more...

DnaAcos is an early stage biotech company developing novel antimicrobial products based on application of its propriety screening assay, SF53.

DnaAcos, founded in 2007, owns the rights to a new antibacterial screen for identification of antibiotics with novel mode of action. The screen, SF5...
Read more...